Sun Pharma says phase-3 trials in skin disorder drug show positive results

The drug, Tildrakizumab, is being developed by Sun Pharma under license from MNC drug major MSD

Sun Pharmaceutical Industries today said that two pivotal phase-3 clinical trials for plaque psoriasis drug have shown positive results.

The drug, Tildrakizumab, is being developed by Sun Pharmaceutical under license from multi national drug major MSD. The trials focused on evaluating the efficacy and safety of the under trial drug in patients with moderate-to-severe plaque psoriasis, a skin disorder.

Read more from our special coverage on "SUN PHARMA"

• Sun Pharma partners ICGEB to develop dengue drug
• Sun Pharma shares up 2% as it gets approval for non-steroid drug
• Sun gets US FDA nod for eye drug
• Sun Pharma buys Novartis brands for Rs 1,900 cr
• Sun Pharma to sell AstraZenecas diabetes drug in India

"We are encouraged by these results and the potential to provide a new treatment option to patients with moderate-to-severe plaque psoriasis, a disease that often takes both a physical and emotional toll on their lives," stated Dilip Shanghvi, Managing Director, Sun Pharma. Over 1,800 patients participated in the trials at more than 200 clinical sites.

Sun Pharma acquired worldwide rights to tildrakizumab for use in all human indications from MSD in exchange for an upfront payment of $80 million.